[New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma]

Bull Cancer. 2021 Oct;108(10):906-907. doi: 10.1016/j.bulcan.2021.06.010. Epub 2021 Oct 2.
[Article in French]
No abstract available

Keywords: duvelisib; inhibiteur de PI3 kinase; leucémie lymphoïde chronique; lymphome folliculaire.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Drug Approval*
  • Drug Resistance, Neoplasm
  • Europe
  • Humans
  • Isoquinolines / therapeutic use*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / mortality
  • Phosphatidylinositol 3-Kinases / therapeutic use*
  • Purines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Recurrence

Substances

  • Antibodies, Monoclonal, Humanized
  • Isoquinolines
  • Purines
  • duvelisib
  • ofatumumab